摘要 |
<p>The present invention provides novel heteroaryl compounds of formula (Ia) which are selective inhibitors of the human P2Y<sub>1</sub> receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y<sub>1</sub> receptor activity. (Ia) or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein: ring A is a 5- to 6-membered heteroaryl comprising: carbon atoms and 1-4 ringheteroatoms selected from N, NR<sup>11</sup>, S(O)<sub>p</sub>, and O, wherein said heteroaryl is substituted with 0-4 R<sup>1</sup>; ring B is phenyl substituted with 0-4 R<sup>7</sup>, pyridyl substituted with 0-3 R<sup>7</sup>, or thienyi substituted with 0-2 R<sup>7</sup>; X is NH or NMe; Y is O or S; R<sup>5</sup> is a -(CR<sup>f</sup>R<sup>f</sup>)n-C<sup>3</sup>-10 carbocycle substituted with 1-4 R<sup>5a</sup>, or a -(CR<sup>f</sup>R<sup>f</sup>)n-5- to 10-membered heterocycle comprising: carbon atoms and 1-4 heteroatoms selected from N, NR<sup>11</sup>, O, and S(O)<sub>p</sub>, wherein said heterocycle is substituted with 0-4 R5<sup>a</sup>; the other substituents and variables are defined in the claims.</p> |